Seagen Inc (Pfizer Inc) (Inactive) (:NASD)の戦略的SWOT分析

Report Overview

Report Summary

Seagen Inc (Pfizer Inc) (Inactive) Strategic SWOT Insights – A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends Report is a comprehensive and easily accessible overview of Seagen Inc (Pfizer Inc) (Inactive) ‘s business operations. It provides a detailed analysis of the company’s strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company’s performance.

The report begins with in-depth information about Seagen Inc (Pfizer Inc) (Inactive) including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company’s key attributes.

Next, the report assesses Seagen Inc (Pfizer Inc) (Inactive)’s strategic standing through various analyses. The ESG spotlight evaluates the company’s environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company’s internal strengths and weaknesses, as well as external opportunities and threats. By integrating these strategic analyses, the report offers a comprehensive understanding of Seagen Inc (Pfizer Inc) (Inactive)’s overall strategic standing and supports informed decision-making and strategic planning.

Finally, the report includes recent news and deal activities undertaken by Seagen Inc (Pfizer Inc) (Inactive) enhancing awareness of the company’s business trends, growth perspectives, and more.

Key Highlights

Seagen Inc (Pfizer Inc) is a leading biotechnology company specializing in transformative cancer therapies, founded in 1997 and now headquartered in New York, United States, following its acquisition by Pfizer in 2023. Originally based in Bothell, Washington, Seagen built its reputation as a global pioneer in antibody-drug conjugate (ADC) technology—innovative targeted therapies that deliver potent anti-cancer agents directly to tumor cells while minimizing harm to healthy tissue. With Pfizer’s acquisition valued at billion, Seagen became an integral part of Pfizer’s oncology division, enhancing its global portfolio of precision-based cancer treatments. Operating across more than 120 countries, the combined Pfizer-Seagen entity focuses on advancing oncology research through cutting-edge biotechnological innovation. Its business segments include oncology therapeutics, biologics research, and clinical development partnerships. The company employs professionals worldwide within Pfizer’s oncology network and continues to expand its pipeline with more than 60 oncology programs in development. Together, Pfizer and Seagen are reimagining the future of cancer care by accelerating scientific breakthroughs, improving patient access, and striving toward a world where cancer can be effectively cured or managed.

Seagen Inc (Pfizer Inc) (Inactive) in the News:-

2025-12-03 – Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award
2025-08-27 – Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
2025-08-12 – PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
2025-07-25 – Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
2025-07-10 – XTANDI Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Scope

• Tactical Analysis:- Various strategic frameworks to gain insights into a company’s competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
• Business Strategy:- Contributes to shaping the company’s overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
• Company Fundamentals:- These fundamentals offer valuable insights into the company’s history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
• Competitive Landscape:- An identification of the company’s main competitors, providing insights into the competitive landscape it operates in.

Reasons to Buy

• Comprehensive Understanding of the Seagen Inc (Pfizer Inc) (Inactive)’s internal and external factors through SWOT analysis and Corporate Strategy.
• Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
• Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
• Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
• Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Additionally, available deep-dive analysis on the company Seagen Inc (Pfizer Inc) (Inactive):

• Seagen Inc (Pfizer Inc) (Inactive) PESTLE Analysis
• Seagen Inc (Pfizer Inc) (Inactive) Value Chain Analysis
• Seagen Inc (Pfizer Inc) (Inactive) Porter’s Five Forces Analysis
• Seagen Inc (Pfizer Inc) (Inactive) VRIO Analysis
• Seagen Inc (Pfizer Inc) (Inactive) BCG Analysis
• Seagen Inc (Pfizer Inc) (Inactive) Segmentation, Targeting and Positioning (STP) Analysis
• Seagen Inc (Pfizer Inc) (Inactive) Ansoff Matrix Analysis

Table of Contents

Tables 5
Charts 6
Seagen Inc (Pfizer Inc) (Inactive) – Key Company Facts 7
Seagen Inc (Pfizer Inc) (Inactive) – Company Description 8
Seagen Inc (Pfizer Inc) (Inactive) – Top Executives 9
Seagen Inc (Pfizer Inc) (Inactive) – Head Office & Locations 10
Head Office – Country 10
Seagen Inc (Pfizer Inc) (Inactive) – Products and Services 11
Products 11
Services 12
Seagen Inc (Pfizer Inc) (Inactive) – Corporate Strategy 13
Seagen Inc (Pfizer Inc) (Inactive) – Business Description 17
Strategic Collaborations and Partnerships 17
Research and Development 18
Oncology Therapeutics 19
Seagen Inc (Pfizer Inc) (Inactive) – ESG Spotlight 20
Environment 20
Social 21
Corporate Governance 22
Seagen Inc (Pfizer Inc) (Inactive) – SWOT Analysis 23
Overview 23
Strengths 25
Weaknesses 28
Opportunities 30
Threats 31
Competing Players 33
Snapshot of Competing Players 34
Amgen Inc 34
Key Company Facts 34
Company Description 34
Amgen Inc. – SWOT Spotlight 35
Amgen Inc. – PESTLE Spotlight 37
Key Financials 39
Share Price Trend – Jun-2025 to Jun-2026 (Average Share Closing Price) 39
Key Financial Ratio Analysis 44
AstraZeneca Plc 46
Key Company Facts 46
Company Description 46
AstraZeneca Plc – SWOT Spotlight 47
AstraZeneca Plc – PESTLE Spotlight 49
Key Financials 51
Share Price Trend – Jun-2025 to Jun-2026 (Average Share Closing Price) 51
Key Financial Ratio Analysis 56
Bristol-Myers Squibb Company 58
Key Company Facts 58
Company Description 58
Bristol-Myers Squibb Company – SWOT Spotlight 59
Bristol-Myers Squibb Company – PESTLE Spotlight 61
Key Financials 63
Share Price Trend – Jun-2025 to Jun-2026 (Average Share Closing Price) 63
Key Financial Ratio Analysis 68
Novartis AG 70
Key Company Facts 70
Company Description 70
Novartis AG – SWOT Spotlight 71
Novartis AG – PESTLE Spotlight 73
Key Financials 75
Share Price Trend – Jun-2025 to Jun-2026 (Average Share Closing Price) 75
Key Financial Ratio Analysis 80
F. Hoffmann-La Roche Ltd 82
Key Company Facts 82
Company Description 82
Seagen Inc (Pfizer Inc) (Inactive) – In the News 83
03-Dec-2025- Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award 83
27-Aug-2025- Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 84
12-Aug-2025- PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery 85
25-Jul-2025- Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union 87
10-Jul-2025- XTANDI Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence 91
31-May-2025- Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer 93
10-Apr-2025- Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24 96
01-Apr-2025- European Commission Approves Pfizer’s RSV Vaccine ABRYSVO to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease 97
13-Feb-2025- Pfizer’s TALZENNA in Combination with XTANDI Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer 99
25-Sep-2024- Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA (voxelotor) From Worldwide Markets 101
20-Sep-2024- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union 102
14-Sep-2024- Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia 104
14-Sep-2024- Pfizer’s BRAFTOVI + MEKTOVI Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer 106
11-Sep-2024- Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 109
Appendix 111
Definitions 111
SWOT Analysis 111
PESTLE Analysis 111
Value Chain Analysis 111
ESG Spotlight 111
Research Methodology 112
Disclaimer 113
Contact Us 113

List of Tables

Table 1: Seagen Inc (Pfizer Inc) (Inactive) – Company Facts 7
Table 2: Seagen Inc (Pfizer Inc) (Inactive) – Digital Presence 7
Table 3: Seagen Inc (Pfizer Inc) (Inactive) – Top Executives 9
Table 4: Seagen Inc (Pfizer Inc) (Inactive) – Products 11
Table 5: Seagen Inc (Pfizer Inc) (Inactive) – Services 12
Table 6: Seagen Inc (Pfizer Inc) (Inactive) -Competing Players 33
Table 7: Competing Players – Amgen Inc. – Key Company Facts 34
Table 8: Amgen Inc. – Share Price Trend – Jun-2025 to Jun-2026 39
Table 9: Competing Players – Amgen Inc. – Profit and Loss Statement 41
Table 10: Amgen Inc. – Balance Sheet 2022-2025 42
Table 11: Amgen Inc. – Cash Flow Statement 2022-2025 43
Table 12: Amgen Inc. – Ratio Analysis – 2022-2025 44
Table 13: Competing Players – AstraZeneca Plc – Key Company Facts 46
Table 14: AstraZeneca Plc – Share Price Trend – Jun-2025 to Jun-2026 51
Table 15: Competing Players – AstraZeneca Plc – Profit and Loss Statement 53
Table 16: AstraZeneca Plc – Balance Sheet 2022-2025 54
Table 17: AstraZeneca Plc – Cash Flow Statement 2022-2025 55
Table 18: AstraZeneca Plc – Ratio Analysis – 2022-2025 56
Table 19: Competing Players – Bristol-Myers Squibb Company – Key Company Facts 58
Table 20: Bristol-Myers Squibb Company – Share Price Trend – Jun-2025 to Jun-2026 63
Table 21: Competing Players – Bristol-Myers Squibb Company – Profit and Loss Statement 65
Table 22: Bristol-Myers Squibb Company – Balance Sheet 2022-2025 66
Table 23: Bristol-Myers Squibb Company – Cash Flow Statement 2022-2025 67
Table 24: Bristol-Myers Squibb Company – Ratio Analysis – 2022-2025 68
Table 25: Competing Players – Novartis AG – Key Company Facts 70
Table 26: Novartis AG – Share Price Trend – Jun-2025 to Jun-2026 75
Table 27: Competing Players – Novartis AG – Profit and Loss Statement 77
Table 28: Novartis AG – Balance Sheet 2022-2025 78
Table 29: Novartis AG – Cash Flow Statement 2022-2025 79
Table 30: Novartis AG – Ratio Analysis – 2022-2025 80
Table 31: Competing Players – F. Hoffmann-La Roche Ltd – Key Company Facts 82

List of Figures

Figure 1: Seagen Inc (Pfizer Inc) (Inactive) – SWOT Analysis 24
Figure 2: Competing Players – Amgen Inc. – SWOTSpotlight 36
Figure 3: Competing Players – Amgen Inc. – PESTLE Spotlight 38
Figure 4: Amgen Inc. – Average Share Price Trend -Jun-2025 to Jun-2026 40
Figure 5: Amgen Inc. – Profit and Loss Statement – 2022-2025 41
Figure 6: Amgen Inc. – Balance Sheet – 2022-2025 42
Figure 7: Amgen Inc. – Cash Flow Statement 2022-2025 43
Figure 8: Competing Players – AstraZeneca Plc – SWOTSpotlight 48
Figure 9: Competing Players – AstraZeneca Plc – PESTLE Spotlight 50
Figure 10: AstraZeneca Plc – Average Share Price Trend -Jun-2025 to Jun-2026 52
Figure 11: AstraZeneca Plc – Profit and Loss Statement – 2022-2025 53
Figure 12: AstraZeneca Plc – Balance Sheet – 2022-2025 54
Figure 13: AstraZeneca Plc – Cash Flow Statement 2022-2025 55
Figure 14: Competing Players – Bristol-Myers Squibb Company – SWOTSpotlight 60
Figure 15: Competing Players – Bristol-Myers Squibb Company – PESTLE Spotlight 62
Figure 16: Bristol-Myers Squibb Company – Average Share Price Trend -Jun-2025 to Jun-2026 64
Figure 17: Bristol-Myers Squibb Company – Profit and Loss Statement – 2022-2025 65
Figure 18: Bristol-Myers Squibb Company – Balance Sheet – 2022-2025 66
Figure 19: Bristol-Myers Squibb Company – Cash Flow Statement 2022-2025 67
Figure 20: Competing Players – Novartis AG – SWOTSpotlight 72
Figure 21: Competing Players – Novartis AG – PESTLE Spotlight 74
Figure 22: Novartis AG – Average Share Price Trend -Jun-2025 to Jun-2026 76
Figure 23: Novartis AG – Profit and Loss Statement – 2022-2025 77
Figure 24: Novartis AG – Balance Sheet – 2022-2025 78
Figure 25: Novartis AG – Cash Flow Statement 2022-2025 79